Mounjaro Dosing After 5 mg
After tolerating the 5 mg weekly dose for at least 4 weeks, increase Mounjaro to 7.5 mg subcutaneously once weekly. 1
Standard Dose Escalation Protocol
The FDA-approved titration schedule for Mounjaro (tirzepatide) follows a structured 4-week escalation pattern 1:
- Weeks 1–4: 2.5 mg once weekly (initiation dose, not for glycemic control)
- Weeks 5–8: 5 mg once weekly
- Weeks 9–12: 7.5 mg once weekly
- Weeks 13–16: 10 mg once weekly
- Weeks 17–20: 12.5 mg once weekly
- Weeks 21+: 15 mg once weekly (maximum dose)
Each dose increment is 2.5 mg and must be separated by at least 4 weeks to minimize gastrointestinal adverse events (nausea, vomiting, diarrhea), which occur most frequently during dose escalation. 1, 2
When to Advance the Dose
Increase the dose if additional glycemic control is needed after at least 4 weeks on the current dose. 1 The decision to escalate should be based on:
- HbA1c target not achieved: If HbA1c remains above individualized goal (typically <7.0% for most patients with type 2 diabetes), advance to the next dose. 3
- Tolerability of current dose: Gastrointestinal side effects (nausea, diarrhea, vomiting) should have resolved or become mild before escalation. 2, 4
- Weight loss goals: For patients using tirzepatide for obesity management, higher doses (10 mg and 15 mg) produce greater weight reduction—10 mg yields ~19.5% mean weight loss and 15 mg yields ~20.9% at 72 weeks. 2
Critical Timing Rules
- Never accelerate titration faster than every 4 weeks. Shortening the interval markedly increases gastrointestinal adverse events and treatment discontinuation. 2, 4
- If a dose is missed: Administer as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and resume the regular schedule. 1
- If treatment is interrupted for any duration: Restart at 2.5 mg and repeat the full titration schedule to avoid severe gastrointestinal intolerance. 2
Maintenance Dosing
FDA-approved maintenance doses are 5 mg, 10 mg, and 15 mg once weekly, with 15 mg as the maximum. 2, 1 The choice of maintenance dose depends on:
- Glycemic efficacy: Mean HbA1c reductions at 40–52 weeks are approximately -2.11% (5 mg), -2.20% to -2.40% (10 mg), and -2.34% to -2.37% (15 mg) versus baseline. 5, 6
- Weight loss efficacy: Mean weight reductions are ~15% (5 mg), ~19.5% (10 mg), and ~20.9–22.5% (15 mg) at 72 weeks. 2
- Tolerability: Discontinuation due to adverse events is higher at 15 mg (
18%) compared with 10 mg (12%) and 5 mg (~10%). 5
Common Pitfalls to Avoid
- Skipping the 2.5 mg starting dose: This increases the likelihood of clinically significant gastrointestinal side effects and should never be done. 2
- Escalating too quickly: Advancing the dose before 4 weeks raises adverse-event rates and the risk of treatment discontinuation. 2, 4
- Failing to reduce concomitant insulin or sulfonylureas: When starting tirzepatide, reduce concurrent insulin doses by 20–30% and consider discontinuing sulfonylureas to prevent hypoglycemia. 2
Special Populations
- Advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²): No dose adjustment is required; tirzepatide is preferred over insulin due to lower hypoglycemia risk. 7
- Type 2 diabetes with obesity: Weight-loss efficacy is modestly reduced compared with obesity alone—12.8% (10 mg) and 14.7% (15 mg) at 72 weeks in the SURMOUNT-2 trial. 2
- Heart failure with preserved ejection fraction (HFpEF) and obesity: The SUMMIT trial protocol used the same escalation schedule (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, each for 4 weeks). 8